Alembic Pharmaceuticals Management
Management criteria checks 3/4
Alembic Pharmaceuticals' CEO is Chirayu Amin, appointed in Apr 2016, has a tenure of 9.67 years. total yearly compensation is ₹140.60M, comprised of 64.4% salary and 35.6% bonuses, including company stock and options. directly owns 2.32% of the company’s shares, worth ₹4.11B. The average tenure of the management team and the board of directors is 2.3 years and 8.2 years respectively.
Key information
Chirayu Amin
Chief executive officer
₹140.6m
Total compensation
| CEO salary percentage | 64.44% |
| CEO tenure | 9.7yrs |
| CEO ownership | 2.3% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
Nov 12
Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results
Aug 08Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable
Jul 11Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results
May 11What Alembic Pharmaceuticals Limited's (NSE:APLLTD) 25% Share Price Gain Is Not Telling You
Mar 31
Future US Launches And GLP-1 Investments Will Strengthen Market Position
Aggressive U.S. product launch strategy and peptide investments to counter price erosion and drive future high-margin revenue growth.Alembic Pharmaceuticals Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Feb 06Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
Jan 11Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | ₹6b |
| Jun 30 2025 | n/a | n/a | ₹6b |
| Mar 31 2025 | ₹141m | ₹91m | ₹6b |
| Dec 31 2024 | n/a | n/a | ₹6b |
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹194m | ₹94m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹6b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹5b |
| Mar 31 2023 | ₹88m | ₹88m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹3b |
| Jun 30 2022 | n/a | n/a | ₹3b |
| Mar 31 2022 | ₹280m | ₹80m | ₹5b |
| Dec 31 2021 | n/a | n/a | ₹8b |
| Sep 30 2021 | n/a | n/a | ₹9b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹315m | ₹65m | ₹11b |
| Dec 31 2020 | n/a | n/a | ₹12b |
| Sep 30 2020 | n/a | n/a | ₹11b |
| Jun 30 2020 | n/a | n/a | ₹10b |
| Mar 31 2020 | ₹265m | ₹65m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹7b |
| Jun 30 2019 | n/a | n/a | ₹6b |
| Mar 31 2019 | ₹255m | ₹55m | ₹6b |
Compensation vs Market: Chirayu's total compensation ($USD1.56M) is above average for companies of similar size in the Indian market ($USD532.22K).
Compensation vs Earnings: Chirayu's compensation has been consistent with company performance over the past year.
CEO
Chirayu Amin (79 yo)
Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 9.7yrs | ₹140.60m | 2.32% ₹ 4.1b | |
| MD & Executive Director | 10.7yrs | ₹191.30m | 0.51% ₹ 908.1m | |
| Executive Director | no data | ₹82.80m | no data | |
| MD & Executive Director | 1.8yrs | ₹191.30m | 0.51% ₹ 910.8m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior Vice President of SCM & Operations | less than a year | no data | no data | |
| Chief Scientific Officer | no data | ₹8.41m | no data | |
| Company Secretary & Compliance Officer | 2.7yrs | no data | no data | |
| Head-Legal & Taxation | no data | no data | no data | |
| Chief Business Development Officer | no data | ₹8.30m | 0.51% ₹ 908.0m | |
| Senior Vice President of Finance | no data | ₹9.20m | no data | |
| Head of International Business & Strategy | 2.3yrs | no data | no data |
Experienced Management: APLLTD's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 15.5yrs | ₹140.60m | 2.32% ₹ 4.1b | |
| MD & Executive Director | 12.6yrs | ₹191.30m | 0.51% ₹ 908.1m | |
| Executive Director | 15.5yrs | ₹82.80m | no data | |
| MD & Executive Director | 14.8yrs | ₹191.30m | 0.51% ₹ 910.8m | |
| Independent Director | 1.8yrs | ₹2.76m | no data | |
| Independent Director | 3.8yrs | ₹3.05m | no data | |
| Independent Director | 2.6yrs | ₹2.79m | no data | |
| Independent Director | less than a year | ₹300.00k | no data |
Experienced Board: APLLTD's board of directors are considered experienced (8.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/04 17:57 |
| End of Day Share Price | 2025/12/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alembic Pharmaceuticals Limited is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |